R20
Payments companies reported to CMS as associated with R20. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with R20, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with R20
These are the largest totals companies reported as associated with R20. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Daniel Kowal | Templeton, MA | Diagnostic Radiology | $69,555.22 |
| Elena Sinkovskaya | Norfolk, VA | Maternal & Fetal Medicine | $13,867.97 |
| Eftichia Kontopoulos | Miami, FL | Maternal & Fetal Medicine | $9,987.20 |
| Ruben Quintero | Miami, FL | Maternal & Fetal Medicine | $5,485.55 |
| Martin Chavez | Mineola, NY | Maternal & Fetal Medicine | $5,250.00 |
| Kevin Magee | Dallas, TX | Maternal & Fetal Medicine | $5,043.95 |
| Ilan Timor | New York, NY | Maternal & Fetal Medicine | $4,813.16 |
| Anthony Sciscione | Newark, DE | Maternal & Fetal Medicine | $4,387.50 |
| Douglas Hoffman | Duluth, MN | Sports Medicine (Family Medicine) | $3,475.78 |
| Jon Jacobson | Ann Arbor, MI | Diagnostic Radiology | $2,306.24 |
Prescribed R20?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.